Ramipril - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for ramipril and what is the scope of patent protection?
Ramipril
is the generic ingredient in two branded drugs marketed by King Pharms Llc, Accord Hlthcare, Actavis Elizabeth, Aurobindo Pharma Ltd, Chartwell Molecular, Chartwell Rx, Cipla, Corepharma, Dr Reddys Labs Ltd, Hikma, Lupin, Ranbaxy Labs Ltd, Teva Pharms, Watson Labs, Zydus Pharms Usa, King Pfizer, Apotex, Natco Pharma, and Zydus Pharms Usa Inc, and is included in nineteen NDAs. Additional information is available in the individual branded drug profile pages.There are nineteen drug master file entries for ramipril. Nineteen suppliers are listed for this compound.
Summary for ramipril
| US Patents: | 0 |
| Tradenames: | 2 |
| Applicants: | 19 |
| NDAs: | 19 |
| Drug Master File Entries: | 19 |
| Finished Product Suppliers / Packagers: | 19 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Clinical Trials: | 169 |
| Drug Prices: | Drug price trends for ramipril |
| Drug Sales Revenues: | Drug sales revenues for ramipril |
| What excipients (inactive ingredients) are in ramipril? | ramipril excipients list |
| DailyMed Link: | ramipril at DailyMed |
Recent Clinical Trials for ramipril
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Menarini International Operations Luxembourg SA | Phase 4 |
| John Paul II Hospital, Krakow | Phase 3 |
| Pharmtechnology LLC | Phase 1 |
Pharmacology for ramipril
| Drug Class | Angiotensin Converting Enzyme Inhibitor |
| Mechanism of Action | Angiotensin-converting Enzyme Inhibitors |
Medical Subject Heading (MeSH) Categories for ramipril
Anatomical Therapeutic Chemical (ATC) Classes for ramipril
US Patents and Regulatory Information for ramipril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | RAMIPRIL | ramipril | CAPSULE;ORAL | 077900-001 | Jun 18, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Natco Pharma | RAMIPRIL | ramipril | TABLET;ORAL | 090650-004 | Jun 30, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Zydus Pharms Usa | RAMIPRIL | ramipril | CAPSULE;ORAL | 078832-004 | Sep 2, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Teva Pharms | RAMIPRIL | ramipril | CAPSULE;ORAL | 077470-002 | Jun 18, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Chartwell Rx | RAMIPRIL | ramipril | CAPSULE;ORAL | 077514-004 | Jun 18, 2008 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apotex | RAMIPRIL | ramipril | TABLET;ORAL | 091069-001 | Dec 2, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lupin | RAMIPRIL | ramipril | CAPSULE;ORAL | 077626-001 | Jun 9, 2008 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ramipril
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-003 | Jan 28, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-004 | Feb 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-002 | Feb 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-001 | Feb 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-001 | Jan 28, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| King Pharms Llc | ALTACE | ramipril | CAPSULE;ORAL | 019901-002 | Jan 28, 1991 | ⤷ Sign Up | ⤷ Sign Up |
| King Pfizer | ALTACE | ramipril | TABLET;ORAL | 022021-003 | Feb 27, 2007 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
